1. Home
  2. CUVL

as of 10-19-2026 2:13pm EST

$5.25
+$0.06
+1.16%
Stocks Miscellaneous Miscellaneous Nasdaq

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Founded: 1999 Country:
Australia
Australia
Employees: 16 City: N/A
Market Cap: 374.2M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 5.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
0.55%
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $4.91 - $8.20 Next Earning Date: 08-27-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 0.89% Revenue Growth (next year): 6.69%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: -13.46%

Share on Social Networks: